Trial Information
Prospective Randomized Study on Therapeutic Gain Achieved By Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma
Inclusion Criteria:
- Undifferentiated or non-keratinizing carcinoma
- Tumor staged as N2-3
- No evidence of distant metastasis M0
- Performance status:0-2
- Marrow: WBC >= 4 and platelet >= 100
- Renal: creatinine clearance >= 60
- Informed consent
Exclusion Criteria:
- WHO type I squamous cell carcinoma or adenocarcinoma
- Age >= 70
- Palliative intent or tumor extent mandating AP opposing facio-cervical fields
- Prior malignancy except adequately treated basal cell or squamous cell skin cancer,
in situ cervical cancer, or other cancer for which the patient has been disease-free
for 5 years
- Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT
treatment volume
- Previous chemotherapy
- Patient is pregnant or lactating
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Failure free survival rate
Outcome Time Frame:
5 year
Principal Investigator
Wai Hon LAU, Dr
Investigator Role:
Principal Investigator
Investigator Affiliation:
Department of Clinical Oncology, Queen Elizabeth Hospital
Authority:
Hong Kong: Ethics Committee
Study ID:
L/M-77 TO PYH08/79
NCT ID:
NCT00563927
Start Date:
March 1999
Completion Date:
October 2009
Related Keywords:
- Nasopharyngeal Neoplasms
- Carcinoma, Squamous Cell
- Nasopharyngeal Carcinoma
- T1-4N2-3M0
- Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Nasopharyngeal Neoplasms